Using PET/CT imaging to evaluate estrogen receptors in breast cancer
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
This study is testing a special type of imaging to see how well it can measure estrogen receptors in patients with breast cancer to help improve their treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tongji Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT05541367 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the efficacy of 18F-Fluoroestradiol (18F-FES) PET/CT imaging in evaluating estrogen receptor (ER) expression levels in patients with primary and metastatic breast cancer. The study focuses on understanding the heterogeneity of estrogen receptors and their role in treatment response and pharmacokinetics of estrogen receptor-targeted therapies. By utilizing a highly sensitive and specific imaging tracer, the study seeks to provide insights into the biological characteristics of breast cancer and improve treatment strategies for patients. Participants will undergo PET/CT scans to measure ER levels, contributing to a better understanding of breast cancer pathology.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with pathologically confirmed breast cancer.
Not a fit: Patients who are pregnant or have severe underlying diseases that prevent cooperation with PET examination may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance personalized treatment approaches for breast cancer patients by providing better insights into estrogen receptor status.
How similar studies have performed: Other studies utilizing PET imaging for evaluating estrogen receptors in breast cancer have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * More than 18 years old * Patients with pathologically confirmed breast cancer * Sign the informed consent form Exclusion Criteria: * Pregnant women * Severe underlying diseases that cannot cooperate with PET examination
Where this trial is running
Wuhan, Hubei
- TongjiHospital — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: Zhu Xiaohua, Dr — Tongji Hospital
- Study coordinator: Zhu Xiaohua, Dr
- Email: evazhu@vip.sina.com
- Phone: 13971513770
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.